![](https://cdn.sanity.io/images/0vv8moc6/onclive/ea452102cd389952bea15b2acdbf37e91d1fbd8b-200x200.png?fit=crop&auto=format)
Bladder-Sparing Treatment Post–Pembrolizumab Progression Is Effective in BCG-Unresponsive NMIBC
A post hoc analysis of the phase 2 KEYNOTE-057 trial (NCT02625961) found bladder-sparing treatment to be equally as effective at preventing disease recurrence as radical cystectomy in patients with high-risk, Bacillus Calmette-Guérin (BCG)–unresponsive non …